Study characteristics of included investigations (multivessel vs. culprit-vessel primary PCI)
| Source . | Year . | Region/country . | Study design . | Enrolment period . | Number of patients . | STEMI (%) . | Measured outcomes . | Follow-up duration . | |
|---|---|---|---|---|---|---|---|---|---|
| Culprit . | Multivessel . | ||||||||
| Cavender | 2009 | United States (NCDR), >600 centres | Retrospective | 2004–2007 | 2654 | 433 | CV: 100% | Mortality, stroke, renal failure | Until discharge |
| MV: 100% | |||||||||
| Bauer | 2012 | Europe (EHS-PCI), 176 centres | Retrospective | May 2005–Apr 2008 | 254 | 82 | CV: 87% | Mortality, non-fatal MI, non-fatal stroke, major bleeding, new renal replacement therapy, CABG | Until discharge |
| MV: 83% | |||||||||
| Cavender | 2013 | United States, single centre | Retrospective | Jan 2002–May 2010 | 156 | 43 | CV: 100% | Mortality | 2.6 years |
| MV: 100% | |||||||||
| Mylotte | 2013 | France, 5 centres | Retrospective | 1998–2010 | 103 (33 CTO) | 66 (17 CTO) | CV: 100% | Mortality, recurrent cardiac arrest, reinfarction, early urgent revascularization | 6 months |
| MV: 100% | |||||||||
| Yang | 2014 | South Korea | Retrospective | Nov 2005–Sep 2010 | 278 | 60 | CV: 100% | Mortality, major acute cardiovascular events, repeat revascularization, bleeding, stroke | 224 days |
| MV: 100% | |||||||||
| Park | 2015 | South Korea (KAMIR), 53 centres | Retrospective | Jan 2006–Dec 2012 | 386 | 124 | CV: 100% | Mortality, cardiac death, recurrent MI, bleeding, stroke, repeat revascularization and MACE | 12–24 months |
| MV: 100% | |||||||||
| Zeymer | 2015 | Germany (ALKK-PCI), 41 centres | Retrospective | Jan 2008–Dec 2011 | 562 | 173 | CV: 77% | Mortality, cardiac arrest, acute vessel closure, urgent CABG, reinfarction, stroke, bleeding, new renal replacement therapy | Until discharge |
| MV: 70% | |||||||||
| Zeymer | 2017 | Germany (IABP-SHOCK II), 41 centres | Retrospective | – | 284 | 167 | CV: 77% | Mortality, reinfarction, bleeding, new renal replacement therapy, quality of life, repeat revascularization | 1 year |
| MV: 73% | |||||||||
| Thiele | 2017 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 30 days |
| MV: 63% | |||||||||
| Thiele | 2018 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 1-year |
| MV: 63% | |||||||||
| Lee | 2018 | South Korea (KAMIR-NIH), 20 centres | Retrospective | Nov 2011–Dec 2015 | 399 | 260 | CV: 100% | Mortality, cardiac mortality, recurrent MI, repeat revascularization, new renal replacement therapy | 1 year |
| MV: 100% | |||||||||
| McNeice | 2018 | Canada (British Columbia Cardiac Registry), 5 centres | Retrospective | 2008– 2014 | 414 | 235 | CV: 76% | Mortality | 1 year |
| MV: 65% | |||||||||
| Lemor | 2020 | United States (NCSI), 57 centres | Retrospective | Jul 2016–Dec 2019 | 72 | 126 | CV: 72% | Mortality, acute kidney injury, length of stay | Until discharge |
| MV: 77% | |||||||||
| Khera | 2020 | United States (NCDR), 649 centres | Retrospective | Jul 2009–Mar 2018 | 41,883 | 22,418 | CV: 80% | Mortality, stroke, tamponade, new renal replacement therapy, bleeding, all-cause readmission, heart-failure readmission, repeat revascularization | 1 year |
| MV: 69% | |||||||||
| Rathod | 2020 | United Kingdom (BCIS PCI), 8 centres | Retrospective | Jan 2005–Jul 2015 | 561 | 497 | CV: 100% | Mortality, stroke, repeat revascularization, emergency CABG, arterial complications, bleeding | Until discharge |
| MV: 100% | |||||||||
| Alegria | 2021 | Portugal (ProACS), multicentric | Retrospective | Oct 2010–Jan 2018 | 23 | 104 | CV: 96% | Mortality, major bleeding, stroke, cardiac arrest, sustained ventricular tachycardia, atrioventricular block, reinfarction, mechanical complication | Until discharge |
| MV: 92% | |||||||||
| Gasior | 2021 | Poland (PL-ACS), multicentric | Retrospective | 2008–2019 | 883 | 1045 | CV: 72% | Mortality, recurrent MI, heart failure readmission, repeat revascularization, stroke | 1 year |
| MV: 68% | |||||||||
| Source . | Year . | Region/country . | Study design . | Enrolment period . | Number of patients . | STEMI (%) . | Measured outcomes . | Follow-up duration . | |
|---|---|---|---|---|---|---|---|---|---|
| Culprit . | Multivessel . | ||||||||
| Cavender | 2009 | United States (NCDR), >600 centres | Retrospective | 2004–2007 | 2654 | 433 | CV: 100% | Mortality, stroke, renal failure | Until discharge |
| MV: 100% | |||||||||
| Bauer | 2012 | Europe (EHS-PCI), 176 centres | Retrospective | May 2005–Apr 2008 | 254 | 82 | CV: 87% | Mortality, non-fatal MI, non-fatal stroke, major bleeding, new renal replacement therapy, CABG | Until discharge |
| MV: 83% | |||||||||
| Cavender | 2013 | United States, single centre | Retrospective | Jan 2002–May 2010 | 156 | 43 | CV: 100% | Mortality | 2.6 years |
| MV: 100% | |||||||||
| Mylotte | 2013 | France, 5 centres | Retrospective | 1998–2010 | 103 (33 CTO) | 66 (17 CTO) | CV: 100% | Mortality, recurrent cardiac arrest, reinfarction, early urgent revascularization | 6 months |
| MV: 100% | |||||||||
| Yang | 2014 | South Korea | Retrospective | Nov 2005–Sep 2010 | 278 | 60 | CV: 100% | Mortality, major acute cardiovascular events, repeat revascularization, bleeding, stroke | 224 days |
| MV: 100% | |||||||||
| Park | 2015 | South Korea (KAMIR), 53 centres | Retrospective | Jan 2006–Dec 2012 | 386 | 124 | CV: 100% | Mortality, cardiac death, recurrent MI, bleeding, stroke, repeat revascularization and MACE | 12–24 months |
| MV: 100% | |||||||||
| Zeymer | 2015 | Germany (ALKK-PCI), 41 centres | Retrospective | Jan 2008–Dec 2011 | 562 | 173 | CV: 77% | Mortality, cardiac arrest, acute vessel closure, urgent CABG, reinfarction, stroke, bleeding, new renal replacement therapy | Until discharge |
| MV: 70% | |||||||||
| Zeymer | 2017 | Germany (IABP-SHOCK II), 41 centres | Retrospective | – | 284 | 167 | CV: 77% | Mortality, reinfarction, bleeding, new renal replacement therapy, quality of life, repeat revascularization | 1 year |
| MV: 73% | |||||||||
| Thiele | 2017 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 30 days |
| MV: 63% | |||||||||
| Thiele | 2018 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 1-year |
| MV: 63% | |||||||||
| Lee | 2018 | South Korea (KAMIR-NIH), 20 centres | Retrospective | Nov 2011–Dec 2015 | 399 | 260 | CV: 100% | Mortality, cardiac mortality, recurrent MI, repeat revascularization, new renal replacement therapy | 1 year |
| MV: 100% | |||||||||
| McNeice | 2018 | Canada (British Columbia Cardiac Registry), 5 centres | Retrospective | 2008– 2014 | 414 | 235 | CV: 76% | Mortality | 1 year |
| MV: 65% | |||||||||
| Lemor | 2020 | United States (NCSI), 57 centres | Retrospective | Jul 2016–Dec 2019 | 72 | 126 | CV: 72% | Mortality, acute kidney injury, length of stay | Until discharge |
| MV: 77% | |||||||||
| Khera | 2020 | United States (NCDR), 649 centres | Retrospective | Jul 2009–Mar 2018 | 41,883 | 22,418 | CV: 80% | Mortality, stroke, tamponade, new renal replacement therapy, bleeding, all-cause readmission, heart-failure readmission, repeat revascularization | 1 year |
| MV: 69% | |||||||||
| Rathod | 2020 | United Kingdom (BCIS PCI), 8 centres | Retrospective | Jan 2005–Jul 2015 | 561 | 497 | CV: 100% | Mortality, stroke, repeat revascularization, emergency CABG, arterial complications, bleeding | Until discharge |
| MV: 100% | |||||||||
| Alegria | 2021 | Portugal (ProACS), multicentric | Retrospective | Oct 2010–Jan 2018 | 23 | 104 | CV: 96% | Mortality, major bleeding, stroke, cardiac arrest, sustained ventricular tachycardia, atrioventricular block, reinfarction, mechanical complication | Until discharge |
| MV: 92% | |||||||||
| Gasior | 2021 | Poland (PL-ACS), multicentric | Retrospective | 2008–2019 | 883 | 1045 | CV: 72% | Mortality, recurrent MI, heart failure readmission, repeat revascularization, stroke | 1 year |
| MV: 68% | |||||||||
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; NCDR, national cardiovascular data registry; CV, culprit vessel; MV, multivessel; EHS-PCI, Euro heart survey percutaneous coronary intervention; CABG, coronary artery bypass grafting; CTO, chronic total occlusion; KAMIR, Korea acute myocardial infarction registry; MACE, major acute cardiovascular events; ALKK-PCI, Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte percutaneous coronary intervention; IABP-SHOCK II trial, intra-aortic balloon pump in cardiogenic shock II trial; KAMIR-NIG, Korea acute myocardial infarction-National Institutes of Health; NCSI, national cardiogenic shock initiative; ProACS, Portuguese registry on acute coronary syndromes; PL-ACS, Polish registry of acute coronary syndrome.
Study characteristics of included investigations (multivessel vs. culprit-vessel primary PCI)
| Source . | Year . | Region/country . | Study design . | Enrolment period . | Number of patients . | STEMI (%) . | Measured outcomes . | Follow-up duration . | |
|---|---|---|---|---|---|---|---|---|---|
| Culprit . | Multivessel . | ||||||||
| Cavender | 2009 | United States (NCDR), >600 centres | Retrospective | 2004–2007 | 2654 | 433 | CV: 100% | Mortality, stroke, renal failure | Until discharge |
| MV: 100% | |||||||||
| Bauer | 2012 | Europe (EHS-PCI), 176 centres | Retrospective | May 2005–Apr 2008 | 254 | 82 | CV: 87% | Mortality, non-fatal MI, non-fatal stroke, major bleeding, new renal replacement therapy, CABG | Until discharge |
| MV: 83% | |||||||||
| Cavender | 2013 | United States, single centre | Retrospective | Jan 2002–May 2010 | 156 | 43 | CV: 100% | Mortality | 2.6 years |
| MV: 100% | |||||||||
| Mylotte | 2013 | France, 5 centres | Retrospective | 1998–2010 | 103 (33 CTO) | 66 (17 CTO) | CV: 100% | Mortality, recurrent cardiac arrest, reinfarction, early urgent revascularization | 6 months |
| MV: 100% | |||||||||
| Yang | 2014 | South Korea | Retrospective | Nov 2005–Sep 2010 | 278 | 60 | CV: 100% | Mortality, major acute cardiovascular events, repeat revascularization, bleeding, stroke | 224 days |
| MV: 100% | |||||||||
| Park | 2015 | South Korea (KAMIR), 53 centres | Retrospective | Jan 2006–Dec 2012 | 386 | 124 | CV: 100% | Mortality, cardiac death, recurrent MI, bleeding, stroke, repeat revascularization and MACE | 12–24 months |
| MV: 100% | |||||||||
| Zeymer | 2015 | Germany (ALKK-PCI), 41 centres | Retrospective | Jan 2008–Dec 2011 | 562 | 173 | CV: 77% | Mortality, cardiac arrest, acute vessel closure, urgent CABG, reinfarction, stroke, bleeding, new renal replacement therapy | Until discharge |
| MV: 70% | |||||||||
| Zeymer | 2017 | Germany (IABP-SHOCK II), 41 centres | Retrospective | – | 284 | 167 | CV: 77% | Mortality, reinfarction, bleeding, new renal replacement therapy, quality of life, repeat revascularization | 1 year |
| MV: 73% | |||||||||
| Thiele | 2017 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 30 days |
| MV: 63% | |||||||||
| Thiele | 2018 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 1-year |
| MV: 63% | |||||||||
| Lee | 2018 | South Korea (KAMIR-NIH), 20 centres | Retrospective | Nov 2011–Dec 2015 | 399 | 260 | CV: 100% | Mortality, cardiac mortality, recurrent MI, repeat revascularization, new renal replacement therapy | 1 year |
| MV: 100% | |||||||||
| McNeice | 2018 | Canada (British Columbia Cardiac Registry), 5 centres | Retrospective | 2008– 2014 | 414 | 235 | CV: 76% | Mortality | 1 year |
| MV: 65% | |||||||||
| Lemor | 2020 | United States (NCSI), 57 centres | Retrospective | Jul 2016–Dec 2019 | 72 | 126 | CV: 72% | Mortality, acute kidney injury, length of stay | Until discharge |
| MV: 77% | |||||||||
| Khera | 2020 | United States (NCDR), 649 centres | Retrospective | Jul 2009–Mar 2018 | 41,883 | 22,418 | CV: 80% | Mortality, stroke, tamponade, new renal replacement therapy, bleeding, all-cause readmission, heart-failure readmission, repeat revascularization | 1 year |
| MV: 69% | |||||||||
| Rathod | 2020 | United Kingdom (BCIS PCI), 8 centres | Retrospective | Jan 2005–Jul 2015 | 561 | 497 | CV: 100% | Mortality, stroke, repeat revascularization, emergency CABG, arterial complications, bleeding | Until discharge |
| MV: 100% | |||||||||
| Alegria | 2021 | Portugal (ProACS), multicentric | Retrospective | Oct 2010–Jan 2018 | 23 | 104 | CV: 96% | Mortality, major bleeding, stroke, cardiac arrest, sustained ventricular tachycardia, atrioventricular block, reinfarction, mechanical complication | Until discharge |
| MV: 92% | |||||||||
| Gasior | 2021 | Poland (PL-ACS), multicentric | Retrospective | 2008–2019 | 883 | 1045 | CV: 72% | Mortality, recurrent MI, heart failure readmission, repeat revascularization, stroke | 1 year |
| MV: 68% | |||||||||
| Source . | Year . | Region/country . | Study design . | Enrolment period . | Number of patients . | STEMI (%) . | Measured outcomes . | Follow-up duration . | |
|---|---|---|---|---|---|---|---|---|---|
| Culprit . | Multivessel . | ||||||||
| Cavender | 2009 | United States (NCDR), >600 centres | Retrospective | 2004–2007 | 2654 | 433 | CV: 100% | Mortality, stroke, renal failure | Until discharge |
| MV: 100% | |||||||||
| Bauer | 2012 | Europe (EHS-PCI), 176 centres | Retrospective | May 2005–Apr 2008 | 254 | 82 | CV: 87% | Mortality, non-fatal MI, non-fatal stroke, major bleeding, new renal replacement therapy, CABG | Until discharge |
| MV: 83% | |||||||||
| Cavender | 2013 | United States, single centre | Retrospective | Jan 2002–May 2010 | 156 | 43 | CV: 100% | Mortality | 2.6 years |
| MV: 100% | |||||||||
| Mylotte | 2013 | France, 5 centres | Retrospective | 1998–2010 | 103 (33 CTO) | 66 (17 CTO) | CV: 100% | Mortality, recurrent cardiac arrest, reinfarction, early urgent revascularization | 6 months |
| MV: 100% | |||||||||
| Yang | 2014 | South Korea | Retrospective | Nov 2005–Sep 2010 | 278 | 60 | CV: 100% | Mortality, major acute cardiovascular events, repeat revascularization, bleeding, stroke | 224 days |
| MV: 100% | |||||||||
| Park | 2015 | South Korea (KAMIR), 53 centres | Retrospective | Jan 2006–Dec 2012 | 386 | 124 | CV: 100% | Mortality, cardiac death, recurrent MI, bleeding, stroke, repeat revascularization and MACE | 12–24 months |
| MV: 100% | |||||||||
| Zeymer | 2015 | Germany (ALKK-PCI), 41 centres | Retrospective | Jan 2008–Dec 2011 | 562 | 173 | CV: 77% | Mortality, cardiac arrest, acute vessel closure, urgent CABG, reinfarction, stroke, bleeding, new renal replacement therapy | Until discharge |
| MV: 70% | |||||||||
| Zeymer | 2017 | Germany (IABP-SHOCK II), 41 centres | Retrospective | – | 284 | 167 | CV: 77% | Mortality, reinfarction, bleeding, new renal replacement therapy, quality of life, repeat revascularization | 1 year |
| MV: 73% | |||||||||
| Thiele | 2017 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 30 days |
| MV: 63% | |||||||||
| Thiele | 2018 | Europe (CULPRIT-SHOCK), multicentric | Prospective, randomized | Apr 2013–Apr 2017 | 344 | 342 | CV: 62% | Mortality, new renal replacement therapy, recurrent MI, HF readmission, staged or repeat revascularization, stroke, bleeding | 1-year |
| MV: 63% | |||||||||
| Lee | 2018 | South Korea (KAMIR-NIH), 20 centres | Retrospective | Nov 2011–Dec 2015 | 399 | 260 | CV: 100% | Mortality, cardiac mortality, recurrent MI, repeat revascularization, new renal replacement therapy | 1 year |
| MV: 100% | |||||||||
| McNeice | 2018 | Canada (British Columbia Cardiac Registry), 5 centres | Retrospective | 2008– 2014 | 414 | 235 | CV: 76% | Mortality | 1 year |
| MV: 65% | |||||||||
| Lemor | 2020 | United States (NCSI), 57 centres | Retrospective | Jul 2016–Dec 2019 | 72 | 126 | CV: 72% | Mortality, acute kidney injury, length of stay | Until discharge |
| MV: 77% | |||||||||
| Khera | 2020 | United States (NCDR), 649 centres | Retrospective | Jul 2009–Mar 2018 | 41,883 | 22,418 | CV: 80% | Mortality, stroke, tamponade, new renal replacement therapy, bleeding, all-cause readmission, heart-failure readmission, repeat revascularization | 1 year |
| MV: 69% | |||||||||
| Rathod | 2020 | United Kingdom (BCIS PCI), 8 centres | Retrospective | Jan 2005–Jul 2015 | 561 | 497 | CV: 100% | Mortality, stroke, repeat revascularization, emergency CABG, arterial complications, bleeding | Until discharge |
| MV: 100% | |||||||||
| Alegria | 2021 | Portugal (ProACS), multicentric | Retrospective | Oct 2010–Jan 2018 | 23 | 104 | CV: 96% | Mortality, major bleeding, stroke, cardiac arrest, sustained ventricular tachycardia, atrioventricular block, reinfarction, mechanical complication | Until discharge |
| MV: 92% | |||||||||
| Gasior | 2021 | Poland (PL-ACS), multicentric | Retrospective | 2008–2019 | 883 | 1045 | CV: 72% | Mortality, recurrent MI, heart failure readmission, repeat revascularization, stroke | 1 year |
| MV: 68% | |||||||||
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; NCDR, national cardiovascular data registry; CV, culprit vessel; MV, multivessel; EHS-PCI, Euro heart survey percutaneous coronary intervention; CABG, coronary artery bypass grafting; CTO, chronic total occlusion; KAMIR, Korea acute myocardial infarction registry; MACE, major acute cardiovascular events; ALKK-PCI, Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte percutaneous coronary intervention; IABP-SHOCK II trial, intra-aortic balloon pump in cardiogenic shock II trial; KAMIR-NIG, Korea acute myocardial infarction-National Institutes of Health; NCSI, national cardiogenic shock initiative; ProACS, Portuguese registry on acute coronary syndromes; PL-ACS, Polish registry of acute coronary syndrome.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
